1. Motta FL, Martin RP, Filippelli-Silva R, et al. Relative frequency of inherited retinal dystrophies in Brazil. Sci Rep. 2018;8(15939):1–9.
2. Ziccardi L, Cordeddu V, Gaddini L, et al. Gene therapy in retinal dystrophies. Int J Mol Sci. 2019;20(5722):1–25.
3. National Institute for Health and Care Excellence (NICE). Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations [ID1054]: pre-briefing meeting. 2018. https://www.nice.org.uk/guidance. Accessed 29 May 2020.
4. European Medicines Agency. Luxturna: EU assessment report. 2019. https://www.ema.europa.eu. Accessed 29 May 2020.
5. Spark Therapeutics. LUXTURNA (voretigene neparvovec-rzyl) intraocular suspension for subretinal injection: US prescribing information. 2019. https://www.fda.gov. Accessed 29 May 2020.